Stock code 9565, GLOE, rose 54 points to 2237.
Continuing to rise. After the close of trading on the 28th, it was announced that the Delivery Technology Research Institute had been taken over as a subsidiary through a third-party allotment of new shares, which is considered good news. The Delivery Tech Research Society supports the creation of an environment for content creators to produce high-energy new content centered around live streaming, providing services such as the provision of the live streaming data analysis tool "Giken Access" and technical support for live streaming, and is growing steadily, contributing to the development of the company group.
Stock code 151A, DIVE, remained unchanged at 3510.
After opening high, the value decreased. The University of Mindanao, a private university providing education programs specialized in the tourism industry in the Philippines, and ICHIGOICHIE CONSULTING, INC., which executes human resources consulting business focused on Philippine human resources, announced that they have concluded a memorandum of understanding (MOU) for Japanese language education and finding jobs in Japan for tourism professionals. They are planning to consider and promote similar initiatives in other countries in the future.
Stock code 5035, HOUSEI, rose 2 points to 487.
It surged temporarily. Today, we have announced the low-code development platform 'imprai' that facilitates application development using generated AI, and also started accepting applications from companies for the pre-release version. Companies that use it can easily develop their own business improvement applications using the latest generated AI without coding knowledge, enabling low-cost and short-term application development and business application.
Stock code 192A, Integroup, significantly fell down by 1140 points. The company announced their 2024 May period settlement report on 28th May after the end of the trading period, indicating that the revenue increased by 72.6% from the previous period to 2.197 billion yen, and the operating profit increased by 311.7% to 983 million yen. In addition to advertising outlays, they worked on strengthening direct marketing, intent marketing that efficiently approaches potential customers, and actively exploring M&A proposals. They also predict that their sales for the 2025 May period will increase by 31.9% from the previous year to 2.897 billion yen, and operating profit will increase by 19.2% to 1.172 billion yen. However, the market is highly disappointed.
Stock code 7776, Selseed, increased by 80 points to 434. Stock code 4882, Perseus, also rose by 80 points to 519. Both stocks have hit their daily limit. After the end of transactions on 28th May, the company announced that Phase 1 trials of PPMX-T003, an anti-transferrin receptor 1 (TfR1) antibody under development, in patients with true polycythemia (PV) had been completed. The test of the sixth and final patient was terminated by the patient's own intention, and the study ended after completing the mandated observations. The company states that there were no serious adverse events reported that raised safety concerns and that there are no changes in the outcome plan, such as the impact on performance this year or by the end of March 2025.
Mainland education revenue corporation Koss Corp's stock code 6666, Sell Seed, increased by 80 points to 434.
After the close of trading on the 28th, the stock hit its daily upward limit, reaching a new high for the year. The company announced that its patent application for a cartilage cell sheet under development in the United States has been approved, which is considered a positive development. The patent is the result of joint research on the same type of cartilage cell sheet conducted by Professor Masato Sato of the Department of Orthopedics, Faculty of Medicine, School of Medicine, Tokai University. The cell sheet for the treatment of degenerative knee joint disease currently under development uses the same type of cartilage cell sheet derived from cartilage tissue collected from patients with polydactyly (a disease where the patient is born with more than 5 fingers or toes) based on the manufacturing method of this patent.
Dai's stock code 151A remained unchanged at 3510.
Stop up. After the end of the transaction on the 28th, the company announced that Phase 1 trials of PPMX-T003, an anti-transferrin receptor 1 (TfR1) antibody under development, in patients with true polycythemia (PV) had been completed. The test of the sixth and final patient was terminated by the patient's own intention, and the study ended after completing the mandated observations. The company states that there were no serious adverse events reported that raised safety concerns and that there are no changes in the outcome plan, such as the impact on performance this year or by the end of March 2025.